Yan Cheng, M.D., Ph.D.
Research Assistant Professor of
Pharmacology
Department of Pharmacology
425 Anatomy-Chemistry Bldg
University of Pennsylvania School of Medicine
3620 Hamilton Walk
Philadelphia, PA 19104-6055
Telephone: 215-898-8360
Fax: 215-573-9004
Email: yancheng@spirit.gcrc.upenn.edu
Home > Faculty > Primary > Cheng
Department of Pharmacology
Education:
Research Summary:
The inhibition of prostaglandin (PG) synthesis by aspirin, and other non-steroidal anti-inflammatory drugs (NSAIDs), was first described over 25 years ago. The NSAIDs are now one of the most commonly used medications worldwide. The clinical problems associated with the selective inhibition of cyclooxygenase-2 (COX-2) have attracted considerable public attention. The COX enzymes catalyze the biotransformation of arachidonic acid into the PG endoperoxide intermediates PGG2 and PGH2. These intermediate products are then further metabolized by isomerases and synthases, which are expressed with some tissue specificity and generate distinct prostanoids (PGI2, PGE2, PGD2, PGF2a, TxA2). All of these products activate G protein–coupled receptors; the phenotypes resulting from deletion of these receptors have increased our understanding of prostanoid biology. Utilizing genetically modified mouse and novel targeted lipidomic approaches, combining with diverse cardiovascular injury models, we are investigating the functional role of prostanoids in the diseases related to vascular injury, including thrombosis, vascular proliferation, vascular remodeling, hypertension, and atherosclerosis. These studies will allow us to reveal new therapeutic strategies for restenosis, stroke, hypertension and other cardiovascular diseases. Selected Key Publications:
Curtis A, Cheng Y, Kapoor S, Reilly D, Price TS, FitzGerald GA. Circadian variation of blood pressure and the vascular response to asynchronous stress. PNAS 104(9): 3450-3455, 2007
Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Pure E, Assoian RK. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol 176(4):535-44, 2007
Cheng Y, Wang M, Yu Y, Lawson J, Funk C & FitzGerald GA: Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399, 2006.
Yu Y, Cheng Y, Fan J, Chen X, Andres K, FitzGerald GA & Funk C: Differential impact of prostaglandin H synthase 1 knock down on platelets and parturition: a genetic mimic of low dose aspirin. J Clin Invest 115: 986–995, 2005.
Rudic RD, Brinster D, Cheng Y, Fries S & FitzGerald GA: Prostacyclin restrains intimal hyperplasia and compensatory remodeling in response to physiologic stress. Circ Res 96: 1240-1247, 2005.
Hui Y, Cheng Y, Smalera I, Jian W, Goldhahn L, FitzGerald GA & Funk CD. Human cysteinyl leukotriene 2 receptor (CysLT2R) endothelial overexpression augments vascular hyperpermeability and reduces systemic blood pressure in response to cysteinyl leukotrienes. Circulation 110: 3360-3366, 2004.
Cheng Y, Austin S, Koller BH, Coffman TM, Grosser T, Lawson J & Fitzgerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541, 2002. Awards, Honors, Membership in Honorary Societies:
Laboratory Personnel:
Lab Address:
Department of Pharmacology
426 Anatomy-Chemistry Bldg
University of Pennsylvania School of Medicine
3620 Hamilton Walk
Philadelphia, PA 19104-6055
Lab Telephone: 215-746-0088 Lab Fax: 215-573-9004
Department of Pharmacology
Yan Cheng, M.D., Ph.D.
Education:| 1992 | M.D. | Tongji Medical University, Wuhan, P. R. China |
| 1998 | Ph.D. | Tongji Medical University, Wuhan, P. R. China (Pharmacology) |
The inhibition of prostaglandin (PG) synthesis by aspirin, and other non-steroidal anti-inflammatory drugs (NSAIDs), was first described over 25 years ago. The NSAIDs are now one of the most commonly used medications worldwide. The clinical problems associated with the selective inhibition of cyclooxygenase-2 (COX-2) have attracted considerable public attention. The COX enzymes catalyze the biotransformation of arachidonic acid into the PG endoperoxide intermediates PGG2 and PGH2. These intermediate products are then further metabolized by isomerases and synthases, which are expressed with some tissue specificity and generate distinct prostanoids (PGI2, PGE2, PGD2, PGF2a, TxA2). All of these products activate G protein–coupled receptors; the phenotypes resulting from deletion of these receptors have increased our understanding of prostanoid biology. Utilizing genetically modified mouse and novel targeted lipidomic approaches, combining with diverse cardiovascular injury models, we are investigating the functional role of prostanoids in the diseases related to vascular injury, including thrombosis, vascular proliferation, vascular remodeling, hypertension, and atherosclerosis. These studies will allow us to reveal new therapeutic strategies for restenosis, stroke, hypertension and other cardiovascular diseases. Selected Key Publications:
Curtis A, Cheng Y, Kapoor S, Reilly D, Price TS, FitzGerald GA. Circadian variation of blood pressure and the vascular response to asynchronous stress. PNAS 104(9): 3450-3455, 2007
Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Pure E, Assoian RK. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol 176(4):535-44, 2007
Cheng Y, Wang M, Yu Y, Lawson J, Funk C & FitzGerald GA: Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399, 2006.
Yu Y, Cheng Y, Fan J, Chen X, Andres K, FitzGerald GA & Funk C: Differential impact of prostaglandin H synthase 1 knock down on platelets and parturition: a genetic mimic of low dose aspirin. J Clin Invest 115: 986–995, 2005.
Rudic RD, Brinster D, Cheng Y, Fries S & FitzGerald GA: Prostacyclin restrains intimal hyperplasia and compensatory remodeling in response to physiologic stress. Circ Res 96: 1240-1247, 2005.
Hui Y, Cheng Y, Smalera I, Jian W, Goldhahn L, FitzGerald GA & Funk CD. Human cysteinyl leukotriene 2 receptor (CysLT2R) endothelial overexpression augments vascular hyperpermeability and reduces systemic blood pressure in response to cysteinyl leukotrienes. Circulation 110: 3360-3366, 2004.
Cheng Y, Austin S, Koller BH, Coffman TM, Grosser T, Lawson J & Fitzgerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541, 2002. Awards, Honors, Membership in Honorary Societies:
| • | National Scientist Development Award, American Heart Association (2007-2011) |
| • | Young Investigator Award, Conference of Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association (2001) |
| Weili Yan Research Specialist weiliyan@spirit.gcrc.upenn.edu |
Department of Pharmacology
426 Anatomy-Chemistry Bldg
University of Pennsylvania School of Medicine
3620 Hamilton Walk
Philadelphia, PA 19104-6055
Lab Telephone: 215-746-0088 Lab Fax: 215-573-9004